2929 ARCH STREET, PHILADELPHIA, PA
Cabaletta Bio, Inc. Increases Authorized Shares to 600 Million
Reg. FD, Other Events
Reports First Quarter 2026 Financial Results and Provides Business Update
Investor Presentation
Cabaletta Bio Presents New Data from RESET-PV Trial at ASGCT 2026
Annual Report to Security Holders
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence